Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria

• Men and Women ≥ 18 years of age
• Diagnosed with stage IV Non-Small Cell Lung Cancer
• Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.

Exclusion Criteria

• Subjects with untreated CNS metastases are excluded.
• Subjects with carcinomatous meningitis
• Subjects with an active, known or suspected autoimmune disease.
• Subjects with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.
• Women who are pregnant, plan to become pregnant, and/or breastfeed during the study. Other protocol defined inclusion/exclusion criteria apply